Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies

Next Previous
Trial Profile

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Mesna (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PRESERVE-I
  • Sponsors Ossium Health

Most Recent Events

  • 27 Mar 2025 Planned End Date changed from 1 Aug 2025 to 1 Nov 2027.
  • 27 Mar 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Aug 2026.
  • 11 May 2024 According to Ossium Health media release , the trial is currently enrolling patients at five transplant centers across the United States.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top